NCT07675616 Hemodynamic Effect of Dexmedetomidine Versus Magnesium Sulphate as an Adjuvant to Lidocaine in Preemptive Peribulbar Block in Patients Undergoing Dacryocystorhinostomy Under General Anesthesia
| NCT ID | NCT07675616 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cairo University |
| Condition | Hemodynamic Effect |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-05-16 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2026-05-16 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to compare the hemodynamic effect of dexmedetomidine and magnesium sulphate as an adjuvant to lidocaine in preemptive peribulbar block in patients undergoing Dacryocystorhinostomy (DCR) under general anaesthesia (GA) .
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years. * Both sexes. * American Society of Anesthesiologists (ASA) physical status I or II. * Undergoing elective Dacryocystorhinostomy (DCR) surgery under general anesthesia. Exclusion Criteria: * Patients have local infection. * Allergic reaction or complications of the local anaesthesia (LA). * Coagulopathy defined as international normalized ratio (INR) \> 1.5, platelet count \< 100,000/mm³, or ongoing anticoagulant therapy not adequately discontinued. * Uncontrolled systemic disease, defined as poorly controlled hypertension \[systolic blood pressure (SBP) \> 160 mmHg\], uncontrolled diabetes mellitus (HbA1c \> 8.5%), unstable ischemic heart disease, or decompensated hepatic or renal disease. * Uncooperative patients.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07675616 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hemodynamic Effect. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07675616 currently recruiting?
Yes, NCT07675616 is actively recruiting participants. Contact the research team at drhebasalah593@gmail.com for enrollment information.
Where is the NCT07675616 trial being conducted?
This trial is being conducted at Cairo, Egypt.
Who is sponsoring the NCT07675616 clinical trial?
NCT07675616 is sponsored by Cairo University. The trial plans to enroll 60 participants.